Sou Hu Cai Jing·2025-12-30 00:32Core Viewpoint - Spring Medical (688236) experienced a decline of 4.05% on December 29, 2025, closing at 22.75 yuan, with a trading volume of 28,900 hands and a total transaction amount of 66.501 million yuan [1]. Group 1: Financial Performance - For the first three quarters of 2025, Spring Medical reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [3]. - The net profit attributable to shareholders reached 192 million yuan, reflecting a year-on-year increase of 213.21% [3]. - The net profit after deducting non-recurring gains and losses was 181 million yuan, up 311.07% year-on-year [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 268 million yuan, a year-on-year increase of 109.51% [3]. - The single-quarter net profit attributable to shareholders was 77.0619 million yuan, up 531.12% year-on-year [3]. - The single-quarter net profit after deducting non-recurring gains and losses was 74.5186 million yuan, an increase of 439.4% year-on-year [3]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan, while the gross profit margin is 67.27% [3]. Group 2: Market Activity - On December 29, 2025, the net outflow of main funds was 12.8684 million yuan, accounting for 19.35% of the total transaction amount [1]. - Retail investors saw a net inflow of 6.5589 million yuan, representing 9.86% of the total transaction amount [1]. - The financing data indicates a financing buy of 10.6505 million yuan and a financing repayment of 3.9893 million yuan, resulting in a net financing buy of 6.6611 million yuan [2]. - The margin trading balance is reported at 40.7626 million yuan [2]. Group 3: Analyst Ratings - In the last 90 days, 9 institutions have provided ratings for Spring Medical, with 8 giving a buy rating and 1 giving an increase rating [3]. - The average target price set by institutions over the past 90 days is 31.8 yuan [3].